Compare Trip.com Group Ltd (TCOM) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs Tilray Brands Inc — how do they compare? Trip.com Group Ltd trades at $38.61 (market cap $23.75B), while Tilray Brands Inc trades at $3.63 (market cap $530.54M). The key difference: Trip.com Group Ltd is far larger — about 44.8× Tilray Brands Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trip.com Group Ltd for 79 Days and Tilray Brands Inc for 31 Days on average.
| TCOM | TLRY | |
|---|---|---|
Market Cap | $23.75B | $530.54M |
Volume | 2,089,737 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $21.00 |
52-Week Low | $37.96 | $3.57 |
Typical Hold Time | 79 Days | 31 Days |
Enterprise Value | $15.91B | $684.46M |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com Group (TCOM) trades at $38.09, down 0.44% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamentals with revenue growth from $53.3B in 2024 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations with $1.07 EPS versus $0.98 expected, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The investment outlook remains positive given attractive valuations (P/E 7.36, EV/EBITDA 3.55) and analyst consensus price target of $56.64 representing 49% upside. However, regulatory risks and competitive pressures from dismantled ranking algorithms require monitoring. With 70% analyst buy ratings and strong cash flow generation, TCOM offers value for patient investors despite near-term technical weakness.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
